iSpecimen Inc. — fact timeline

iSpecimen Inc. shareholders rejected Approval of an amendment to the Fourth Amended and Restated Certificate of Incorporation to permit removal of directors by stockholders without cause.

“Proposal No. 4 was not approved, because votes in favor of this proposal did not represent a majority of the voting shares entitled to vote thereon, as required.”

iSpecimen Inc. shareholders approved Approval of an amendment to the Second A&R 2021 Plan to increase the number of shares reserved for issuance from 608,000 to 1,869,500 shares.

“Proposal No. 3 was approved by a majority of the votes cast.”

iSpecimen Inc. shareholders approved Approval of amendments to the Second A&R 2021 Plan to remove automatic annual increase and add clawback provisions.

“Proposal No. 2 was approved by a majority of the votes cast.”

iSpecimen Inc. shareholders approved Election of three Class II directors each to serve for a three-year term that expires at the 2026 annual meeting of stockholders.

“Brooks III 3,900,970 704,582 1,914,191 Tracy Curley 4,056,320 549,232 1,914,191 Theresa L. Mock 4,412,763 192,789 1,914,191 Each nominee was elected.”

iSpecimen Inc. reported first quarter of 2023 results: revenue Revenue was approximately $3.0 million, net income Net loss was approximately $2.4 million, or $(0.27) per share, EPS $(0.27) per share.

“reported its financial and operating results for the three-month period ended March 31, 2023. “I am pleased to report that iSpecimen delivered strong revenue of approximately $3.0 million, a 17% increase year-over-year for the first quarter of 2023, which met our internal expectations and reflects the seasonality of our business,” said Tracy Curley, CEO and CFO.”

Tracy Curley was appointed as Chief Executive Officer at iSpecimen Inc..

“On January 9, 2023, the Board, at a Special Meeting of the Board of Directors, appointed Ms. Curley as Chief Executive Officer of the Company, effective immediately.”

Joseph J. Basile was appointed as Director at iSpecimen Inc..

“approved the appointment of Joseph J. Basile to serve as a member of the Board”

Margaret H. Lawrence resigned as Director at iSpecimen Inc..

“Margaret H. Lawrence informed the Board of Directors (the “Board”) of the Company of her intention to resign as a director of the Company effective November 15, 2022”

iSpecimen Inc. reported three- and nine-month period ended September 30, 2022 results: revenue $2.6 million, net income $3.1 million, or $(0.35) per share, EPS $(0.35) per share.

“Revenue for the third quarter of 2022 was approximately $2.6 million”

Margaret H. Lawrence resigned as director at iSpecimen Inc..

“On October 27, 2022, Margaret H. Lawrence informed the Board of her intention to resign as a director of the Company effective November 15, 2022.”

Tracy Curley was appointed as Interim Chief Executive Officer at iSpecimen Inc..

“The Board appointed Tracy Curley, who currently serves as the Chief Financial Officer and Treasurer of the Company, as Interim Chief Executive Officer of the Company, effective immediately upon Dr. Ianelli’s no longer serving as Chief Executive Officer and President of the Company.”

Jill Mullan departed as Chief Operating Officer at iSpecimen Inc..

“On September 20, 2022, the Board received a similar notice of departure from Jill Mullan to vacate the position of Chief Operating Officer of the Company, effective as of October 24, 2022, as a result of the non-renewal of her Executive Employment Agreement dated June 21, 2021.”

Christopher Ianelli departed as Chief Executive Officer and President at iSpecimen Inc..

“On September 21, 2022, pursuant to the mutual agreement of Dr. Ianelli and the Board, Dr. Ianelli vacated his positions as Chief Executive Officer and President of the Company.”